Healthcare Utilization and Impact of Antifungal Stewardships Within Respiratory Care Settings: A Systematic Literature Review

Salma Aldossary · Anand Shah

Received: 16 January 2021 / Accepted: 17 March 2021 / Published online: 15 May 2021
© The Author(s) 2021

Abstract
Introduction  Fungal infection and sensitization are common in chronic respiratory patient populations such as bronchiectasis, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) and are often associated with prolonged antifungal therapy (Hohmann et al. in Clin Infect Dis 15:939–940, 2010; Vissichelli et al. in Infect Prev Pract 1:100029, 2019), morbidity, and mortality. Although the use of antifungal stewardship (AFS) is increasing within an invasive fungal disease setting, its use and impact within a chronic respiratory setting have not been defined.

Methods  A systematic literature review was conducted using PRISMA guidelines to evaluate the use of antifungal stewardship within a chronic respiratory care setting. Three databases have been searched, Medline via Ovid, Embase and GlobalHealth, for papers published between 1949 and 2020. Results  The initial search identified 987 papers from Medline, 1761 papers from Embase, and 481 papers from GlobalHealth. Only 28 papers met the criteria for inclusion in this systematic literature review. The included studies were subjected to CASP and GRADE assessments to rank their quality and applicability. Only two studies were focussed on Aspergillus species infection.

Conclusion  Although antifungal stewardship is increasing, its applications are still limited in chronic respiratory care settings despite the prolonged requirement for antifungal therapy and high antimicrobial resistance.

Keywords  Stewardship · Antifungal resistance · Aspergillus fumigatus · Antifungal · Chronic · Respiratory disease

Handling Editor: Sanjay H. Chotirmall.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s11046-021-00547-z.

S. Aldossary · A. Shah
Respiratory Medicine, Royal Brompton and Harefield
NHS Foundation Trust, London, UK
E-mail: s.anand@imperial.ac.uk

A. Shah
MRC Centre of Global Infectious Disease Analysis,
Department of Infectious Disease Epidemiology, School
of Public Health, Imperial College London, London, UK

Abbreviations
PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-Analyses
ASP  Antimicrobial stewardship program
AFS  Antifungal stewardship
CASP  Critical Appraisal Skills Programme
GRADE  Grading of Recommendations Assessment, Development and Evaluation
ABPA  Allergic bronchopulmonary aspergillosis
TDM  Therapeutic drug monitoring
MDT  Multidisciplinary team
Introduction

Individuals with chronic respiratory diseases are susceptible to fungal infection and allergy, which can cause a spectrum of diseases depending on the underlying host response. This can typically vary from sensitization, allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), semi-invasive and invasive infection [1, 2]. There is a large global burden of fungal-related chronic lung disease, with global estimates of CPA at ~ 3 million cases [3, 4]. There is furthermore a recent appreciation of the impact of fungal infection and sensitization on morbidity of globally widespread chronic lung disease such as non-CF bronchiectasis and chronic obstructive pulmonary disease (COPD), which is additionally a significant risk factor for invasive fungal infection. Aspergillus-related disease also affects ~ 20% of individuals with cystic fibrosis (CF), leading to increased exacerbation frequency [3].

Oral triazole antifungal drugs are effective against A. fumigatus and are predominantly first-line therapy in the management of Aspergillus–related infection and allergy in chronic respiratory disease. However, there has been a rapid and global emergence of multiple triazole resistance phenotypes in A. fumigatus over the past decade, with a particularly high prevalence noted in patients with chronic lung disease [5]. Individuals with chronic lung disease and fungal infection/allergy often require a prolonged duration of antifungal therapy, with intra-pulmonary fungi within cavitatory or hypoxic microenvironments, likely predisposing to antifungal resistance development [6, 7]. Triazole resistance has been associated with increased mortality both within an invasive and chronic pulmonary aspergillosis setting [8].

Antifungal stewardship aims to provide a meaningful mechanism to guide medication prescription in these at-risk cohorts to improve outcome and reduce toxicity and emergence of antifungal resistance [9, 10]. The principle is based on existing antimicrobial stewardship programs (ASPs), which optimize antibiotic prescriptions by taking into account the range of action, pharmacokinetics, and pharmacodynamics (PK/PD) properties, length, and route of administration. Key to stewardship programs is therapy optimization with population level screening through regular therapeutic drug monitoring (TDM) to ensure that optimum PK/PD is achieved to increase effectiveness and reduce adverse outcomes and antifungal resistance [11, 12]. However, the impact and evidence-base for the use of antifungal stewardship in a chronic respiratory disease setting is not yet well defined. We perform a systematic literature review aiming to evaluate the current evidence of the use and impact of antifungal stewardship within a chronic respiratory disease setting.

Methodology

A systematic literature review based on PRISMA guidelines was conducted [13]. Three databases have been searched, Medline via Ovid, Embase, and GlobalHealth, for papers published between 1949 and 2020. The search strategy (see Supplementary information) was designed to find papers that involve antifungal or antimicrobial stewardship.

- Inclusion criteria involve papers that implemented antifungal stewardship and reported the outcomes or studies that report clinical outcomes of antifungal therapeutic drug monitoring.
- Exclusion criteria involve papers (1) not in English, (2) case reports, (3) narrative or systematic reviews.

Studies were imported to Covidence for screening [14]. After screening, articles were removed for a number of reasons including no focus on antifungal agents or antifungal stewardship, wrong outcomes, wrong study design, systematic review or meta-analysis, not available, wrong patient population, wrong intervention or case reports. The PRISMA checklist was utilized in guiding the systematic literature review. Due to the differences in interventions, patient populations, and outcomes for the studies, the data were descriptively summarized. The findings were drawn after qualitative synthesis of data.

The quality of the included studies was determined using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation methodology), which is categorized to high, moderate, low, and very low [15, 16]. By definition, high classification indicates that further research is very unlikely to change the confidence in the estimate of effect. Moderate quality means further research is likely to have an important impact on the confidence in the
estimate of effect. Low-grade classification indicates that further research is very likely to have an important impact, while very low classification indicates that an effective impact of the findings is very uncertain [15]. The studies collected for this review were tested using this approach to answer the clinical question on the usefulness and impact of the antifungal stewardship programs on patients in respiratory care.

Results

The primary search yielded 3229 papers (987 papers from Medline, 1761 papers from Embase, and 481 papers from GlobalHealth). As illustrated in Fig. 1, only 29 papers met inclusion criteria for this systematic literature review (see Supplementary information for references for all included papers). Table 1 provides a summary of the included papers.

- Disease area of focus

The predominant fungal infection studied in the eligible articles with inclusion of patients with underlying chronic respiratory disease was Candida species with 25 out of 29 articles focusing on invasive fungal disease infection (IFI). Although fourteen studies included sample populations consisting of patients with chronic respiratory illnesses, only two studies (Nwanko et al. and Browne et al.) had a focus specifically on chronic respiratory fungal infections and pulmonary aspergillosis, indicating a gap in existing knowledge/evidence base in the use of antifungal stewardship in this field [9, 17]. Although focused on an invasive fungal infection setting, the implementation of antifungal stewardship was shown to be an effective intervention in a number of the included studies, with some (n = 3) having a moderate GRADE quality of evidence.

Of the two studies that analysed implementation of antifungal stewardship in a chronic respiratory disease setting, Nwanko et al. conducted a prospective cohort study over a 18-month period with 178 patients to determine the impact of an antifungal stewardship team in patients with chronic lung diseases at a tertiary cardio-pulmonary hospital [17]. The researchers implemented an antifungal stewardship team

Fig. 1 PRISMA flow diagram of search and selection process
| Study author, year | Study design | Type of fungal species | Intervention | Duration of intervention | Patient population, Settings | Presence of chronic respiratory patients | Outcomes after Stewardship | GRADE |
|--------------------|--------------|------------------------|--------------|--------------------------|-------------------------------|------------------------------------------|----------------------------------|--------|
| Shah et al. [28]   | Retrospective | Candida species         | Invasive tests | 48 h-24 days             | Immunocompetent adult patients treated in the medical and surgical intensive care units | Yes | Fungal testing of respiratory tract specimens does not add diagnostic value | Low |
| Mondain et al. [29] | Prospective observational | Invasive aspergillosis and candidaemia | Multifaceted antifungal stewardship discussion | 48 h-2 weeks | French teaching tertiary-care hospital | Yes | Antifungal stewardship programme was feasible, sustainable, and well accepted | Low |
| López-Medrano et al. [31] | Intervention | Candida species | Non-randomized uncontrolled before-after antimicrobial stewardship | 1–2 years | The University Hospital 12 de Octubre. A 1300-bed hospital | Yes | Primary outcome of the study was a reduction in antifungal expenditure | Low |
| Alfandari et al. [20] | Retrospective | Candida species | Multidisciplinary collaborative use of antifungals in haematology | 4–5 days | Allograft and acute leukemia induction chemotherapy patients. The Lille Regional Teaching Hospital | No | Decreased antifungal consumption, stabilized invasive fungal infections (IFI), and decreased IFI-related mortality | Low |
| Muñoz et al. [32]   | Retrospective | Candida species         | Educational and bedside intervention | 2 years | Hospitalized patients with cases of invasive candidiasis and invasive aspergillosis | Yes | Reduced consumption of DDDs and reduced expenditure on antifungals | Low |
| Vissichelli et al. [2] | Retrospective | Aspergillus species | Review of bronchoalveolar lavage results | 2 years | Autologous haematopoietic stem-cell transplant recipients | Yes | Antifungals were more likely to be escalated or changed | Low |
| Whitney et al. [24] | Retrospective | Candida species | Antifungal susceptibility testing | 5–6 days | Adult in patients receiving amphotericin B, echinocandins, intravenous fluconazole, flucytosine, or voriconazole. St. George’s tertiary referral hospital | Yes | Antifungal expenditure initially reduced then increased to 20% above baseline over a 5-year period | Low |
| Study author, year | Study design | Type of fungal species | Intervention | Duration of intervention | Patient population, Settings | Presence of chronic respiratory patients | Outcomes after Stewardship | GRADE |
|-------------------|-------------|------------------------|--------------|--------------------------|-----------------------------|------------------------------------------|----------------------------|-------|
| Hamada et al. [33] | Retrospective | N/A                    | Voriconazole trough concentration | 4 days | Hospitalized patients on voriconazole, at five hospitals in Japan | No | Reduced incidence of hepatotoxicity | Low |
| Shah et al. [34]  | Retrospective | Candida species         | Administration of fluconazole or an echinocandin | 5 + or - 2 days | Hospitalized patients with candidaemia | No | Less than 40% of echinocandin-treated patients with fluconazole-susceptible organisms were de-escalated to fluconazole | Low |
| Gurram et al. [43] | Retrospective | Candida species         | Bronchoalveolar lavage | 6–12 months | Adult immunocompromised patients who underwent bronchoscopy with Immunocompromised Host (ICH) Protocol | Yes | Patients with Candida sp. in bronchoscopy cultures are not likely to be intervened upon | Low |
| Rautemaa-Richardson et al. [35] | Retrospective | Candida species         | Antifungal therapy | 4 months | Patients prescribed micafungin for suspected or proven invasive candidosis. UK tertiary referral teaching hospital | Yes | Number of patients treated for invasive candidiasis decreased | Low |
| Mondain et al. [30] | Prospective observational | Candida species         | Systematic evaluation | 2–5 days | Teaching tertiary-care hospital | No | Improved quality of care and stable antifungal use and cost in the hospital | Very low |
| Antworth et al. [36] | Single-centre, quasi-experimental | Candida species         | Comprehensive candidemia care bundle | 3 days | Patients with candidemia. A 930-bed academic hospital | No | Improved management of patients with candidemia | Low |
| Menichetti et al. [21] | Retrospective | Candida species         | Infectious disease consultation | 30 days | Patients with documented candidemia cared for in Pisa tertiary care, University hospital | No | A lower 30-day in-hospital mortality rate for candidemia patients treated with infectious diseases consultation (IDC) with respect to those treated without | Moderate |
| Study author, year | Study design | Type of fungal species | Intervention | Duration of intervention | Patient population, Settings | Presence of chronic respiratory patients | Outcomes after Stewardship | GRADE |
|--------------------|--------------|------------------------|--------------|--------------------------|-----------------------------|------------------------------------------|------------------------------|-------|
| Swoboda et al. [19] | Retrospective | *Candida* species       | Standardized practice of antifungal therapy | 45 days | Patients with an intensive care unit (ICU) stay of 1–24 h and either recovery of fungi from any site and/or application of systemic antifungals | No | Significant decrease in the use of antifungal agents as well as costs | Moderate |
| Browne et al. [9]  | Retrospective | *Candida* species       | Complex lung infection multidisciplinary meeting | 6–12 months | Hospitalized patients with suspected fungal lung disease | Yes | Allowed a refinement in diagnosis of *Aspergillus*-associated lung diseases and improved stewardship of triazole drugs | Very Low |
| Reed et al. [37]   | Quasi-experimental | *Candida* species | ASP pharmacist’s intervention | 1–2 years | The Ohio state Wexner Medical Centre, a 1229-bed teaching hospital | Yes | Timely notification from microbiology to the ASP PharmD in conjunction with ASP PharmD interventions resulted in more patients with candidemia receiving timely effective antifungal therapy | Moderate |
| Veringa et al. [38] | Retrospective | *Candida* species       | Therapeutic drug monitoring (TDM) of anti-infective drugs | 1–2 days | In-patients | No | TDM plays an important role in the optimization of treatment with anti-infective drugs | Low |
| Morris et al. [4]  | Phased, multisite cohort | *Candida* species | Antimicrobial stewardship | 3–5 days | Patients admitted to each ICU at the academic ICUs in Toronto, Canada | Yes | Sustained improvements in antimicrobial consumption and cost | Low |
| Pfaller and Castan Heira [39] | Prospective | *Candida* species       | Rapid diagnostic testing and antifungal stewardship | 24 h, 7 days | Hospitalized individuals | No | Improved care by increasing the awareness of candidiasis, Improve diagnostic efforts | Low |
| Study author, year | Study design | Type of fungal species | Intervention | Duration of intervention | Patient population, Settings | Presence of chronic respiratory patients | Outcomes after Stewardship | GRADE |
|------------------|-------------|------------------------|--------------|--------------------------|------------------------------|----------------------------------------|-------------------------------|--------|
| Märtson et al. [40] | Retrospective | *Candida* species | Therapeutic drug monitoring of posaconazole | 1–3 years | Patients with haematological malignancies. The University Medical Center Groningen, the Netherlands | No | 64% was the adequate posaconazole exposure; in the longitudinal analysis from all the confounders, only dose had a significant effect on posaconazole concentrations | Low |
| Kawaguchi et al. [41] | Single-centre, observational | *Candida* species | Antifungal stewardship programs (AFSPs) | 1–3 years | Patients who received systemic antifungals at the Osaka City University Hospital (980-bed, tertiary-care teaching hospital) | Yes | As the appropriate selection of antifungals increases, a decrease in antifungal usage and cost reduction also occurs. This trend leads to improved prognoses of patients with candidemia | Low |
| Ito-Takeichi et al. [42] | Single-institutional prospective cohort | *Candida* species | 1-3, β-D-glucan (βDG) testing | 1–2 days | In patients receiving intravenous antifungals at the 614-bed Gifu University Hospital | No | Parental antifungal use was significantly reduced | Low |
| Cavalieri et al. [46] | Retrospective | *Candida* species | MALDI-TOF mass spectrometry /Vitek 2 | 1–2 days | Hospitalized patients | Yes | An average 18 h faster microbial ID and antimicrobial susceptibility test results | Low |
| Steuber et al. [18] | Single-centre, retrospective, observational | *Candida* species | T2 Candida Panel (T2CP) | 3 years | Patients with positive or negative T2CP at a 971-bed community hospital | No | Antifungal optimization occurred in 54% of patients who had antifungal orders at the time of T2CP test | Low |
| Study author, year | Study design | Type of fungal species | Intervention | Intervention duration | Patient population, Settings | Presence of chronic respiratory patients | GRADE | Outcomes after Stewardship
|-------------------|--------------|------------------------|--------------|-----------------------|--------------------------------|---------------------------------------------|--------|------------------------------------------|
| Hashemi et al. [45] | Retrospective | Candida species | Disc diffusion and micro-dilution | N/A | Clinical isolates of Candida | No | Very low | The Candida studied had the highest rates of sensitivity to caspofungin and amphotericin B. Among azoles, the highest sensitivity, respectively, is to miconazole, econazole, fluconazole, and then to fluconazole |
| Chabavizadeh et al. [44] | Retrospective | Ganoderma lucidum (alcoholic extract) | N/A | N/A | Patients with candidemia admitted to some specialized hospitals in Tehran | No | Very low | Ganoderma lucidum can be used as an antifungal product in future studies for control and treatment of candidiasis |
| Nwankwo et al. [17] | Prospective | Aspergillus species | Antifungal stewardship team impact assessment | 18 months | Chronic lung disease in patients and outpatients with fungal infections | Yes | Low | The commonest infection was CPA, reduction in monthly antifungal expenditure as well as antifungal use after implementing AFS without increase in mortality/morbidity |
consisting of a mycologist and pharmacist provided weekly stewardship rounds, a multidisciplinary meeting twice a week and an outpatient clinic. The most common underlying fungal disease amongst the cohort was CPA by 32%. The study demonstrates through stewardship implementation the delivery of 285 specific recommendations to improve outcome. A statistical increase in therapeutic azole dosing was noted as a result of stewardship implementation alongside a significant 44% reduction in monthly antifungal expenditure, with no deleterious effect on outcome.

The study by Browne et al., in which complex fungal lung infections, defined as sub-acute invasive aspergillosis (SAIA), CPA, CPA/ABPA overlap, and ABPA/bacterial infection overlap, were managed through a novel MDT, which comprised three respiratory physicians, an infectious disease specialist, a microbiologist and two pharmacists. They met six times in a 12-month period to review patients on antifungal medication with chronic lung infection [9]. Out of the 32 cases the team discussed, 13 were categorized as complex fungal lung infection. Therapeutic drug monitoring was implemented for these cases and a significant reduction in development of resistance was noted.

- Quality of study analysis

The quality of the included studies was determined using the Grading of Recommendations, Assessments, Development, and Evaluations (GRADE) methodology, a widely used systemic approach to making clinical recommendations. The studies collected for this review were tested using this approach to answer the clinical question on the usefulness and impact of the antifungal stewardship programs on patients in respiratory care. According to the GRADE classification, the majority of the included records start with very low and low classification as the majority of them are observational studies. Three studies reached moderate GRADE quality classification, however, due to the impact of findings. Studies’ characteristics are shown in Table 1.

- Reported outcomes:

  Optimization of antifungal use: Eleven articles concluded that antifungal stewardship is associated with increased appropriate use of medication and a reduction in the overuse/misuse of antifungal therapy. The reduction of unnecessary antifungal use importantly did not negatively affect the quality of care or patient outcomes.

  Mortality/morbidity: within the papers identified by the systematic review, some of the intervention measures initiated in the systematic literature review such as optimizing diagnosis through novel rapid diagnostics (e.g. T2CP and use of MALDI-TOF mass spectrometry) resulted in quicker diagnosis and reduced inappropriate antifungal use [18]. Integrated multidisciplinary antifungal stewardship programmes were associated with a reduction in incidence in antifungal-attributed toxicities such as hepatotoxicity, as well as a reduction in 30-day in-hospital mortality rates for candidaemia [19–21].

Discussion

In this systematic review to evaluate the evidence base for antifungal stewardship in a chronic respiratory disease setting, we show that the majority of the studies performed to date are focussed in an invasive fungal disease setting, predominantly with Candida species infection, with only four studies reaching moderate grade evidence. There is nevertheless evidence in this setting indicating the effectiveness of antifungal stewardship as an implementation strategy, with improved appropriate use of optimal antifungal therapy and evidence to suggest benefit in reducing attributable mortality. With clear protocols for indication and dosage alongside therapeutic drug monitoring of antifungal medication, there was improved optimization of antifungal therapy, with corresponding reductions in drug toxicity. It is unclear as yet, whether long-term, improved delivery of optimal antifungal therapy can reduce acquisition or development of antimicrobial resistance.

Our systematic literature review, however, showed very limited current evidence within a chronic respiratory care setting. Only two studies were focussed on chronic lung disease patients with fungal infection. Both of these studies confirm the susceptibility of chronic respiratory patients to fungal infection. However, there are significant limitations in the evidence on antifungal stewardship application in a chronic respiratory care setting [22, 23, 24]. Two of the included studies (Nwanko et al. and Browne et al.) are
classified as low-quality evidence according to GRADE classification [9, 17]. The prospective and retrospective studies highlighting antifungal stewardship in respiratory care settings may contain bias given the small sample size utilized in both studies with imprecisions due to a confidence interval of less than 95% in the results obtained.

Nevertheless, according to several of the included studies, antifungal stewardship is an effective means of regulating antifungal use, advocating for optimal use of the drugs, and reducing unintended harm. Given the duration of antifungal therapy often required within a chronic respiratory setting, this indicates significant potential benefit from stewardship implementation. However, as yet, there is a lack of evidence, and given the high burden of disease with rising antimicrobial resistance levels, there is an urgent requirement for a robust systematic evidence base for widespread adoption. Although antifungal medication is used widely within chronic respiratory fungal allergic diseases with a number of studies highlighting the impact of fungal sensitization on chronic respiratory disease, none of the papers within our systematic review have analysed the effects of antifungal stewardship implementation on fungal sensitization control. Previous studies have suggested the importance of optimal azole therapeutic dosing within ABPA, and this is again a topic that requires further systematic prospective evidence base [25].

To date, there is little evidence on optimal antifungal management of fungal disease in a chronic respiratory setting, with significant variability in management and diagnosis. A survey on laboratory setting capability for fungal testing in the UK in 2017 found that the practice remained sub-optimal, with a lack of a standardized approach to fungal testing unlike bacterial infections and variable testing and documentation of antifungal resistance [26, 27]. We highlight in this systematic review the significant benefits following implementation of antifungal stewardship in an invasive fungal disease setting, with a lack of evidence base for implementation in a growing burden in a chronic respiratory disease setting with high antifungal resistance prevalence.

Conclusion

This systematic literature review shows that antifungal stewardship is an essential extension of ASPs and presents many of the same benefits for patients in an invasive disease setting. However, the application and evidence base for antifungal stewardship are still limited in a chronic respiratory disease setting despite a high burden of fungal disease and antifungal resistance. Further research is urgently needed to understand the factors that lead to the development of antifungal resistance and assess the impact of antifungal stewardship within a chronic respiratory disease setting.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hohmann C, Kang EM, Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis. 2010;50(6):939–40. https://doi.org/10.1086/650740.
2. Vissichelli NC, Miller K, McCarty JM, Roberts CH, Stevens MP, De La Cruz O. Bronchoalveolar lavage to evaluate new pulmonary infiltrates in allogeneic hematopoietic stem cell transplant recipients: impact on antimicrobial optimization. Infect Prev Pract. 2019. https://doi.org/10.1016/j.infpip.2019.100029.
3. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017;3(4):57.
4. Morris AM, Bai A, Burry L, Desser LD, Ferguson ND, Lapinsky SE, et al. Long-term effects of phased implementation of antimicrobial stewardship in academic ICUs: 2007–2015. Crit Care Med. 2019;47(2):159–66.
5. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from LUNGS OF PATIENTS WITH CHRONIC FUNGAL DISEASE. Clin Infect Dis. 2011;52:1123–9.
6. Kowalski CH, Morelli KA, Schultz D, Nadell CD, Cramer RA. Fungal biofilm architecture produces hypoxic microenvironments that drive antifungal resistance. Proc Natl Acad Sci U S A. 2020;117(36):22473–83.

7. Science M, Timberlake K. Antifungal stewardship: a budding branch of antimicrobial stewardship. Pediatr Blood Cancer. 2020;67(4):e28145.

8. Verweij PE, Chowdhary A, Melchers WJG, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62:362–8.

9. Browne A, Wilkie M, Waqar A, Shaw A, Hill K, Rae N, et al. P138 Improving anti-fungal stewardship and the management of chronic pulmonary aspergillosis through a complex lung infection MDT. 2019. https://doi.org/10.1136/thorax-2019-btsabstracts2019.281.

10. Andruszko B, Dodds Ashley E. Antifungal stewardship: an emerging practice in antimicrobial stewardship. Curr Clin Microbiol Rep. 2016;3:111–9.

11. Çeken S, İskender G, Gedik H, Duygu F, Mert D, Kaya AH, et al. Risk factors for bloodstream infections due to extended-spectrum β-lactamase producing enterobacteriaceae in cancer patients. J Infect Dev Ctries. 2018;12(4):265–72.

12. Lagnaoui R, Moore N, Dartgues JF, Fourrier A, Bégaud B. Benzodiazepine use and wine consumption in the French elderly. Br J Clin Pharmacol. 2001;52(4):455–6.

13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021 Mar 17:S0895-4356(21)00073–1.

14. Veritas Health Innovation. Covidence systematic review software. Veritas Health Innovation, Melbourne, Australia. 2020; Available at www.covidence.org. Melb. Aust. 2018.

15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(3):383–94.

16. Nwankwo L, Periselneris J, Cheong J, Thompson K, Darby P, Leaver N, et al. A prospective real-world study of the impact of an antifungal stewardship program in a tertiary respiratory-medicine setting. Antimicrob Agents Chemother. 2018;62(10). https://doi.org/10.1128/AAC.00402-18.

17. Steuber TD, Tucker-Heard G, Edwards J, Sawyer A, Thottacherry E, Hassoun A. Utilization and impact of a rapid Candida panel on antifungal stewardship program within a large community hospital. Diagn Microbiol Infect Dis. 2020;97(4):115086.

18. Steuber TD, Tucker-Heard G, Edwards J, Sawyer A, Thottacherry E, Hassoun A. Utilization and impact of a rapid Candida panel on antifungal stewardship program within a large community hospital. Diagn Microbiol Infect Dis. 2020;97(4):115086.

19. Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009;55(6):418–24.

20. Alfantari S, Berthon C, Coiteux V. Antifungal stewardship: implementation in a French teaching hospital, Med Mal Infect. 2014;44(4):154–8.

21. Menichetti F, Bertolino G, Sozio E, Carmignani C, Rosselli Del Turco E, Tagliaferri E, et al. Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, University hospital. J Chemother. 2018;30(5):304–9.

22. Agnelli C, Valerio M, Bouza E, Vena A, Guinea J, del Carmen M-J, et al. Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era. Eur J Clin Microbiol Infect Dis. 2019;38:607–14.

23. Agrawal S, Barnes R, Brüggemann RJ, Rautema-Richardson R, Warris A. The role of the multidisciplinary team in antifungal stewardship. J Antimicrob Chemother. 2016;71:i37-42.

24. Whitney L, Al-Ghiusein H, Glass S, Koh M, Klammer M, Ball J, et al. Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010–16. J Antimicrob Chemother. 2019;74(1):234–41.

25. Periselneris J, Nwankwo L, Schelenz S, Shah A, Armstrong-James D. Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. J Antimicrob Chemother. 2019;74(6):1701–3.

26. Schelenz S, Owens K, Guy R, Rautema-Richardson R, Manuel RJ, Richardson M, et al. National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: evidence of sub-optimal practice. J Infect. 2019;79(2):167–73.

27. Boyle M, Moore JE, Whitehouse JL, Bilton D, Downey DG. Laboratory diagnosis and characterization of fungal disease in patients with cystic fibrosis (CF): a survey of current UK practice in a cohort of clinical microbiology laboratories. Mycopathologia. 2018;183:723–9.

28. Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146–51. https://doi.org/10.1093/jac/dkr244.

29. Mondain V, Lietteur F, Gari-Toussaint M, Hasseine L, Lions C, Pulcini C. Impact of an antifungal stewardship programme in a teaching hospital: a prospective study. Clin Microbiol Infect. 2012.

30. Mondain V, Lietteur F, Hasseine L, Gari-Toussaint M, Poiree M, Lions C, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41:621–8. https://doi.org/10.1007/s13303-013-0431-1.

31. López-Medrano F, Juan R, Lízasain M, Catalán M, Ferrari J, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013; https://doi.org/10.1111/j.1469-0691.2012.03891.x.

32. Muñoz P, Valero M, Vena A, Bouza E. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015. https://doi.org/10.1111/myc.12329.

33. Hamada Y, Ueda T, Miyazaki Y, Nakajima K, Fukunaga K, Miyazaki T, et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan. Mycoses. 2020;63:779–778. https://doi.org/10.1111/myc.13129.
34. Shah AS, O’Horo JC, Tang S, Bryson AL, Wengenack NL, Sampathkumar P. Fungal diagnostic stewardship in bronchoscopy specimens for immunocompetent patients in the intensive care unit. Mayo Clin Proc. 2019;94:1781–5. https://doi.org/10.1016/j.mayocp.2019.02.020.

35. Rautemaa-Richardson R, Rautemaa V, Al-Wathiqi F, Moore CB, Craig L, Felton TW, et al. Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital. J Antimicrob Chemother. 2018;73:3488–95. https://doi.org/10.1093/jac/dky360.

36. Antworth A, Collins CD, Kunapuli A, Klein K, Carver P, Gandhi T, et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy. 2013;33:137–43. https://doi.org/10.1002/phar.1186.

37. Reed EE, West JE, Keating EA, Pancholi P, Balada-Llasat J-M, Mangino JE, et al. Improving the management of candidemia through antimicrobial stewardship interventions. Diagn Microbiol Infect Dis. 2014;78:157–61. https://doi.org/10.1016/j.diagmicrobio.2013.11.012.

38. Veringa A, Sturkenboom MGG, Dekkers BGJ, Koster RA, Roberts JA, Peloquin CA, et al. LC-MS/MS for therapeutic drug monitoring of anti-infective drugs. TrAC Trends Anal Chem. 2016;84:34–40. https://doi.org/10.1016/j.trac.2015.11.026.

39. Pfänder MA, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol. 2016;62:698–705. https://doi.org/10.1093/mmy/myv076.

40. Martson AG, Veringa A, van den Heuvel ER, Bakker M, Touw DJ, van der Werf TS, et al. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. Mycoses. 2019. https://doi.org/10.1111/myc.12948.

41. Kawaguchi H, Yamada K, Imoto W, Yamairi K, Shibata W, Namikawa H, et al. The effects of antifungal stewardship programs at a tertiary-care teaching hospital in Japan. J Infect Chemother. 2019;25:458–62. https://doi.org/10.1016/j.jiac.2019.01.015.

42. Ito-Takeichi S, Niwa T, Fujibayashi A, Suzuki K, Ohta H, Niwa A, et al. The impact of implementing an antifungal stewardship with monitoring of 1–3, β-D-glucan values on antifungal consumption and clinical outcomes. J Clin Pharm Ther. 2019;44:454–62. https://doi.org/10.1111/jcpt.12809.

43. Gurram P, Vashistha K, O’Horo JC, Shah A. Fungal culture diagnostic Stewardship: an avenue for antimicrobial stewardship in the immunocompromised host. Open Forum Infect Dis. 2019. https://doi.org/10.1093/ofid/ofz360.342.

44. Chabavizadeh J, Sadeghi M, Chadeganipour M, Gohari M, Dehghan P. The antifungal effects of alcoholic extract of Ganoderma lucidum on candida isolates. In: 8th trends in medical mycology, organised under the auspices of EORTC-IDG and ECMM, 6-9 October 2017, Belgrade, Serbia (2017).

45. Hashemi J. Identification of species and evaluation drug susceptibility of Candida isolated from patients with visceral candidiasis by disk diffusion and micro-dilution methods. In: 5th international conference on parasitology & microbiology, July 12–13, 2018 Paris, France (2018).

46. Cavalieri S, Kwon S, Vivekanandan R, Ased S, Carroll C, Schmidt D, et al. Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) and Vitek 2 along with antimicrobial Stewardship (ASP) result in faster antimicrobial therapy for infected patients: the CHI health experience. Open Forum Infect Dis. 1808;2018(5):S513.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.